Tomas N. Gustafsson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tomas N. Gustafsson has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Arne Holmgren
Division of Biochemistry, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, SE-171 77 Stockholm, Sweden
5 shared publications - Jun Lu
Key Laboratory of Luminescence Analysis and Molecular Sensing, Ministry of Education, College of Pharmaceutical Sciences and Chinese Medicine, Southwest University
5 shared publications Arne Holmgren
Division of Biochemistry, Medical Biochemistry & Biophysics, Karolinska Institutet, 171 77 Stockholm, Sweden
3 shared publicationsLars Engman
Department of Chemistry, BMC, Uppsala University, Uppsala, Sweden
3 shared publications- Britt-Marie Sjöberg
Department of Biochemistry and Biophysics, Stockholm University
2 shared publications Margareta Sahlin
Department of Biochemistry and Biophysics, Stockholm University, Stockholm, Sweden
2 shared publications
Latest Publications
- Open Access
- 27 November 2024
- Published by Wiley in Veterinary Medicine and Science
- Vol. 11 (1) , e70094
An Emerging Role for Ticks as Vectors of Tularaemia in Sweden
Background: The zoonotic bacterium Francisella tularensis, the causative agent of tularaemia, can be transmitted to humans via multiple routes, including through contact with infected animals, contaminated water or arthropod vectors. Ticks have not previously been described as transmitting the disease in Sweden. Recently, Ixodid tick species have expanded their latitudinal and altitudinal range in Sweden to areas where the disease is endemic. Tularaemia is a cause of growing concern, spreading to new areas in Sweden and infecting hares and humans.Objectives: To establish whether ticks could be a potential arthropod vector in the transmission of F. tularensis subsp. holarctica in Sweden.Methods: Ticks were collected from northern Sweden and screened for F. tularensis. A follow‐up study with ticks collected from F. tularensis‐positive hares was performed. Ticks were analysed using real‐time PCR and a pathological examination was performed on the hares.Results: F. tularensis subsp. holarctica was identified in ticks from one cat and three F. tularensis‐infected hares. Two hares had skin lesions associated with tick bites with intralesional F. tularensis bacteria.Conclusions: F. tularensis subsp. holarctica was isolated from ticks collected from the hares and cat, the first such reports in ticks in Sweden. Identification of the bacteria at the tick bite site and the more chronic character of the skin lesions compared to those of inner organs suggest that the ticks infected the hares. The cat showed no clinical signs of disease, suggesting that its tick was indeed the vector. These new findings suggest that ticks play a role in the transmission of F. tularensis to human and animal hosts in Sweden.
- 27 November 2024
- Published by Wiley in Veterinary Medicine and Science
- Vol. 11 (1) , e70094
Open AccessAn Emerging Role for Ticks as Vectors of Tularaemia in Sweden
Background: The zoonotic bacterium Francisella tularensis, the causative agent of tularaemia, can be transmitted to humans via multiple routes, including through contact with infected animals, contaminated water or arthropod vectors. Ticks have not previously been described as transmitting the disease in Sweden. Recently, Ixodid tick species have expanded their latitudinal and altitudinal range in Sweden to areas where the disease is endemic. Tularaemia is a cause of growing concern, spreading to new areas in Sweden and infecting hares and humans.Objectives: To establish whether ticks could be a potential arthropod vector in the transmission of F. tularensis subsp. holarctica in Sweden.Methods: Ticks were collected from northern Sweden and screened for F. tularensis. A follow‐up study with ticks collected from F. tularensis‐positive hares was performed. Ticks were analysed using real‐time PCR and a pathological examination was performed on the hares.Results: F. tularensis subsp. holarctica was identified in ticks from one cat and three F. tularensis‐infected hares. Two hares had skin lesions associated with tick bites with intralesional F. tularensis bacteria.Conclusions: F. tularensis subsp. holarctica was isolated from ticks collected from the hares and cat, the first such reports in ticks in Sweden. Identification of the bacteria at the tick bite site and the more chronic character of the skin lesions compared to those of inner organs suggest that the ticks infected the hares. The cat showed no clinical signs of disease, suggesting that its tick was indeed the vector. These new findings suggest that ticks play a role in the transmission of F. tularensis to human and animal hosts in Sweden.
- Open Access
- 23 February 2024
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 78 (5) , 1222-1231
Targeting Tularemia: Clinical, Laboratory, and Treatment Outcomes From an 11-year Retrospective Observational Cohort in Northern Sweden
Tularemia is an important reemerging disease with a multimodal transmission pattern. Treatment outcomes of current recommended antibiotic regimens (including ciprofloxacin and doxycycline) remain unclear. In this retrospective cohort study, we report clinical, laboratory, geographical, and treatment outcomes of laboratory-confirmed tularemia cases over an 11-year period in Northern Sweden. Data from reported tularemia cases (aged >10 years at time of study) in Norrbotten county between 2011 and 2021 were collected through review of electronic medical records and participant questionnaires; 415 of 784 accepted participation (52.9%). Of these, 327 were laboratory-confirmed cases (serology and/or polymerase chain reaction). A multivariable logistic regression model was used to investigate variables associated with retreatment. Median age of participants was 54 years (interquartile range [IQR], 41.5–65) and 49.2% were female. Although ulceroglandular tularemia was the predominant form (n = 215, 65.7%), there were several cases of pulmonary tularemia (n = 40; 12.2%). Inflammatory markers were largely nonspecific, with monocytosis frequently observed (n = 36/75; 48%). Tularemia was often misdiagnosed on presentation (n = 158, 48.3%), with 65 (19.9%) receiving initial inappropriate antibiotics and 102 (31.2%) retreated. Persistent lymphadenopathy was infrequent (n = 22, 6.7%), with 10 undergoing surgical interventions. In multivariable analysis of variables associated with retreatment, we highlight differences in time until receiving appropriate antibiotics (8 [IQR, 3.25–20.75] vs 7 [IQR, 4–11.25] days; adjusted P = .076), and doxycycline-based treatment regimen (vs ciprofloxacin; adjusted P = .084), although this was not significant after correction for multiple comparisons. We comprehensively summarize clinical, laboratory, and treatment outcomes of type B tularemia. Targeting tularemia requires clinical awareness, early diagnosis, and timely commencement of treatment for an appropriate duration.
- 23 February 2024
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 78 (5) , 1222-1231
Open AccessTargeting Tularemia: Clinical, Laboratory, and Treatment Outcomes From an 11-year Retrospective Observational Cohort in Northern Sweden
Tularemia is an important reemerging disease with a multimodal transmission pattern. Treatment outcomes of current recommended antibiotic regimens (including ciprofloxacin and doxycycline) remain unclear. In this retrospective cohort study, we report clinical, laboratory, geographical, and treatment outcomes of laboratory-confirmed tularemia cases over an 11-year period in Northern Sweden. Data from reported tularemia cases (aged >10 years at time of study) in Norrbotten county between 2011 and 2021 were collected through review of electronic medical records and participant questionnaires; 415 of 784 accepted participation (52.9%). Of these, 327 were laboratory-confirmed cases (serology and/or polymerase chain reaction). A multivariable logistic regression model was used to investigate variables associated with retreatment. Median age of participants was 54 years (interquartile range [IQR], 41.5–65) and 49.2% were female. Although ulceroglandular tularemia was the predominant form (n = 215, 65.7%), there were several cases of pulmonary tularemia (n = 40; 12.2%). Inflammatory markers were largely nonspecific, with monocytosis frequently observed (n = 36/75; 48%). Tularemia was often misdiagnosed on presentation (n = 158, 48.3%), with 65 (19.9%) receiving initial inappropriate antibiotics and 102 (31.2%) retreated. Persistent lymphadenopathy was infrequent (n = 22, 6.7%), with 10 undergoing surgical interventions. In multivariable analysis of variables associated with retreatment, we highlight differences in time until receiving appropriate antibiotics (8 [IQR, 3.25–20.75] vs 7 [IQR, 4–11.25] days; adjusted P = .076), and doxycycline-based treatment regimen (vs ciprofloxacin; adjusted P = .084), although this was not significant after correction for multiple comparisons. We comprehensively summarize clinical, laboratory, and treatment outcomes of type B tularemia. Targeting tularemia requires clinical awareness, early diagnosis, and timely commencement of treatment for an appropriate duration.
- Open Access
- 1 June 2017
- Published by Elsevier in Cell Reports
- Vol. 19 (13) , 2771-2781
Hepatocyte Hyperproliferation upon Liver-Specific Co-disruption of Thioredoxin-1, Thioredoxin Reductase-1, and Glutathione Reductase
- 1 June 2017
- Published by Elsevier in Cell Reports
- Vol. 19 (13) , 2771-2781
Open AccessHepatocyte Hyperproliferation upon Liver-Specific Co-disruption of Thioredoxin-1, Thioredoxin Reductase-1, and Glutathione Reductase
- Open Access
- 7 June 2016
- Published by Oxford University Press (OUP) in FEMS Microbiology Letters
- Vol. 363 (14)
Auranofin andN-heterocyclic carbene gold-analogs are potent inhibitors of the bacteriaHelicobacter pylori
Auranofin is an FDA-approved gold-containing compound used for the treatment of rheumatoid arthritis. Recent reports of antimicrobial activity against protozoa and bacteria indicate that auranofin targets the reductive enzyme thioredoxin reductase (TrxR). We evaluated auranofin as well as five auranofin analogs containing N-heterocyclic carbenes (instead of the triethylphosphane present in auranofin) and five gold-carbene controls for their ability to inhibit or kill Helicobacter pylori in vitro. Auranofin completely inhibited bacterial growth at 1.2 μM. Purified H. pylori TrxR was inhibited by auranofin in a cell-free assay (IC50 ∼88 nM). The most active gold(I)-N-heterocyclic carbene compounds exhibited MICs comparable to auranofin against H. pylori (2 μM), while also exhibiting lower toxicities for human embryonic kidney cells (HEK-293T cells). Median toxic concentrations (TC50) were 13–20-fold higher compared to auranofin indicating that they were less cytotoxic. The N-heterocyclic carbene analogs maybe well tolerated, but further evaluation is needed in vivo. Finally, auranofin was synergistic with the antibiotic amoxicillin, suggesting that targeting both the reductive enzyme TrxR and cell wall synthesis may be effective against H. pylori infections.
- 7 June 2016
- Published by Oxford University Press (OUP) in FEMS Microbiology Letters
- Vol. 363 (14)
Open AccessAuranofin andN-heterocyclic carbene gold-analogs are potent inhibitors of the bacteriaHelicobacter pylori
Auranofin is an FDA-approved gold-containing compound used for the treatment of rheumatoid arthritis. Recent reports of antimicrobial activity against protozoa and bacteria indicate that auranofin targets the reductive enzyme thioredoxin reductase (TrxR). We evaluated auranofin as well as five auranofin analogs containing N-heterocyclic carbenes (instead of the triethylphosphane present in auranofin) and five gold-carbene controls for their ability to inhibit or kill Helicobacter pylori in vitro. Auranofin completely inhibited bacterial growth at 1.2 μM. Purified H. pylori TrxR was inhibited by auranofin in a cell-free assay (IC50 ∼88 nM). The most active gold(I)-N-heterocyclic carbene compounds exhibited MICs comparable to auranofin against H. pylori (2 μM), while also exhibiting lower toxicities for human embryonic kidney cells (HEK-293T cells). Median toxic concentrations (TC50) were 13–20-fold higher compared to auranofin indicating that they were less cytotoxic. The N-heterocyclic carbene analogs maybe well tolerated, but further evaluation is needed in vivo. Finally, auranofin was synergistic with the antibiotic amoxicillin, suggesting that targeting both the reductive enzyme TrxR and cell wall synthesis may be effective against H. pylori infections.
- 1 June 2016
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - General Subjects
- Vol. 1860 (6) , 1265-1271
Ebselen and analogs as inhibitors of Bacillus anthracis thioredoxin reductase and bactericidal antibacterials targeting Bacillus species, Staphylococcus aureus and Mycobacterium tuberculosis
- 1 June 2016
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - General Subjects
- Vol. 1860 (6) , 1265-1271
Ebselen and analogs as inhibitors of Bacillus anthracis thioredoxin reductase and bactericidal antibacterials targeting Bacillus species, Staphylococcus aureus and Mycobacterium tuberculosis
- 26 February 2016
- Published by Springer Nature in Chromatographia
- Vol. 79 (7-8) , 383-393
A Bioanalytical Method for Quantification of Thioredoxins in Bacillus anthracis by Digestion with Immobilized Pepsin and LC–MS/MS and On-line LC/LC–MS/MS
- 26 February 2016
- Published by Springer Nature in Chromatographia
- Vol. 79 (7-8) , 383-393
A Bioanalytical Method for Quantification of Thioredoxins in Bacillus anthracis by Digestion with Immobilized Pepsin and LC–MS/MS and On-line LC/LC–MS/MS
- 1 March 2014
- Published by Elsevier in Analytical Biochemistry
- Vol. 449, 139-146
Activity assays of mammalian thioredoxin and thioredoxin reductase: Fluorescent disulfide substrates, mechanisms, and use with tissue samples
- 1 March 2014
- Published by Elsevier in Analytical Biochemistry
- Vol. 449, 139-146
Activity assays of mammalian thioredoxin and thioredoxin reductase: Fluorescent disulfide substrates, mechanisms, and use with tissue samples
- Open Access
- 1 September 2013
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 288 (38) , 27456-27468
Ebsulfur Is a Benzisothiazolone Cytocidal Inhibitor Targeting the Trypanothione Reductase of Trypanosoma brucei
- 1 September 2013
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 288 (38) , 27456-27468
Open AccessEbsulfur Is a Benzisothiazolone Cytocidal Inhibitor Targeting the Trypanothione Reductase of Trypanosoma brucei
- Open Access
- 17 December 2012
- Published by Wiley in The FASEB Journal
- Vol. 27 (4) , 1394-1403
Inhibition of bacterial thioredoxin reductase: an antibiotic mechanism targeting bacteria lacking glutathione
Increasing antibiotic resistance makes the identification of new antibacterial principles an urgent task. The thioredoxin system including thioredoxin reductase (TrxR), thioredoxin (Trx), and NADPH plays critical roles in cellular DNA synthesis and defense against oxidative stress. Notably, TrxR is very different in structure and mechanism in mammals and bacteria. Ebselen [2‐phenyl‐1,2 benzisoselenazol‐3(2 H )‐one], a well‐known antioxidant and a substrate for mammalian TrxR and Trx, is rapidly bacteriocidal for methicillin‐resistant Staphylococcus aureus by an unknown mechanism. We have discovered that ebselen is a competitive inhibitor of Escherichia coli TrxR with a K i of 0.52 ± 0.13 μM, through reaction with the active site dithiol of the enzyme. Bacteria lacking glutathione (GSH) and glutaredoxin, in which TrxR and Trx are essential for DNA synthesis, were particularly sensitive to ebselen. In growth‐inhibited E. coli strains, Trx1 and Trx2 were oxidized, demonstrating that electron transfer via thioredoxin was blocked. Ebselen and its sulfur analog ebsulfur were bactericidal for GSH‐negative pathogens. Ebsulfur inhibited a clinically isolated Helicobacter pylori strain with a minimum inhibitory concentration value as low as 0.39 μg/ml. These results demonstrate that bacterial Trx and TrxR are viable antibacterial drug targets using benzisoselenazol and benzisothiazol derivates.—Lu, J., Vlamis‐Gardikas, A., Kandasamy, K., Zhao, R., Gustafsson, T. N., Engstrand, L., Hoffner, S., Engman, L., Holmgren, A. Inhibition of bacterial thioredoxin reductase: an antibiotic mechanism targeting bacteria lacking glutathione. FASEB J. 27, 1394–1403 (2013). www.fasebj.org
- 17 December 2012
- Published by Wiley in The FASEB Journal
- Vol. 27 (4) , 1394-1403
Open AccessInhibition of bacterial thioredoxin reductase: an antibiotic mechanism targeting bacteria lacking glutathione
Increasing antibiotic resistance makes the identification of new antibacterial principles an urgent task. The thioredoxin system including thioredoxin reductase (TrxR), thioredoxin (Trx), and NADPH plays critical roles in cellular DNA synthesis and defense against oxidative stress. Notably, TrxR is very different in structure and mechanism in mammals and bacteria. Ebselen [2‐phenyl‐1,2 benzisoselenazol‐3(2 H )‐one], a well‐known antioxidant and a substrate for mammalian TrxR and Trx, is rapidly bacteriocidal for methicillin‐resistant Staphylococcus aureus by an unknown mechanism. We have discovered that ebselen is a competitive inhibitor of Escherichia coli TrxR with a K i of 0.52 ± 0.13 μM, through reaction with the active site dithiol of the enzyme. Bacteria lacking glutathione (GSH) and glutaredoxin, in which TrxR and Trx are essential for DNA synthesis, were particularly sensitive to ebselen. In growth‐inhibited E. coli strains, Trx1 and Trx2 were oxidized, demonstrating that electron transfer via thioredoxin was blocked. Ebselen and its sulfur analog ebsulfur were bactericidal for GSH‐negative pathogens. Ebsulfur inhibited a clinically isolated Helicobacter pylori strain with a minimum inhibitory concentration value as low as 0.39 μg/ml. These results demonstrate that bacterial Trx and TrxR are viable antibacterial drug targets using benzisoselenazol and benzisothiazol derivates.—Lu, J., Vlamis‐Gardikas, A., Kandasamy, K., Zhao, R., Gustafsson, T. N., Engstrand, L., Hoffner, S., Engman, L., Holmgren, A. Inhibition of bacterial thioredoxin reductase: an antibiotic mechanism targeting bacteria lacking glutathione. FASEB J. 27, 1394–1403 (2013). www.fasebj.org
- Open Access
- 1 November 2012
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 287 (47) , 39686-39697
Bacillus anthracis Thioredoxin Systems, Characterization and Role as Electron Donors for Ribonucleotide Reductase
- 1 November 2012
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 287 (47) , 39686-39697
Open AccessBacillus anthracis Thioredoxin Systems, Characterization and Role as Electron Donors for Ribonucleotide Reductase